Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Carlos Carretero-Puche
Observed names:
C. Carretero-Puche,
Carlos Carretero Puche,
Carlos Carretero‐Puche,
Carretero-Puche Cd,
Carretero-Puche, Carlos
Institutions:
Research Institute Hospital 12 de Octubre,
Spanish National Cancer Research Centre,
Hospital Universitario 12 De Octubre
Observed institutions:
Research Institute Hospital 12 de Octubre,
Spanish National Cancer Research Centre,
Hospital Universitario 12 De Octubre
ORCID:
0000-0003-0474-8668
Observed ORCID:
0000-0003-0474-8668
OpenAlex ID:
A5033946433
Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data
2021
·
Coral Fustero-Torre
, María José Jiménez-Santos
, et al.
·
Genome Medicine
·
151
PDF
The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications
2019
·
B. Soldevilla
, C. Carretero-Puche
, et al.
·
European Journal of Cancer
·
97
PDF
Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
2023
·
Rocio Garcia-Carbonero
, Beatriz Anton-Pascual
, et al.
·
Endocrine Reviews
·
56
Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance
2021
·
Beatriz Soldevilla
, Angeles López-López
, et al.
·
Cancers
·
21
PDF
DREIMT: a drug repositioning database and prioritization tool for immunomodulation
2020
·
Kevin Troulé
, Hugo López-Fernández
, et al.
·
Bioinformatics
·
20
PDF
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
2023
·
Anna La Salvia
, Alberto Lens-Pardo
, et al.
·
European Journal of Endocrinology
·
11
PDF
How can bioinformatics contribute to the routine application of personalized precision medicine?
2020
·
Carlos Carretero-Puche
, Santiago García-Martín
, et al.
·
Expert Review of Precision Medicine and Drug Development
·
9
PDF
vulcanSpot: a tool to prioritize therapeutic vulnerabilities in cancer
2019
·
Javier Perales-Patón
, Tomás Di Domenico
, et al.
·
Bioinformatics
·
9
Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
2025
·
Beatriz Rubio-Cuesta
, Carlos Carretero-Puche
, et al.
·
British Journal of Cancer
·
8
PDF
MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms
2023
·
Beatriz Soldevilla
, Alberto Lens‐Pardo
, et al.
·
Molecular Oncology
·
5
PDF
1144O Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms
2024
·
A. Lens-Pardo
, C. Carretero-Puche
, et al.
·
Annals of Oncology
·
1
PDF
28MO Predictive biomarkers of response to axitinib in patients with advanced EP-NETs enrolled in the AXINET trial (GETNE 1107): Underlying molecular mechanisms
2023
·
A. Lens-Pardo
, C. Carretero-Puche
, et al.
·
ESMO Open
·
1
Decoding neuroendocrine tumors: a cross-site multiomic approach unveils clinically relevant molecular subtypes
2026
·
Carlos Carretero-Puche
, Beatriz Anton-Pascual
, et al.
·
Genome Medicine
Code for: Decoding neuroendocrine tumors: a cross-site multiomic approach unveils clinically relevant molecular subtypes
2026
·
carcarre11
, Carretero-Puche, Carlos
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
1143O Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models: Unveiling novel neuroendocrine subtypes and their clinical implications
2024
·
C. Carretero-Puche
, B. Antón Pascual
, et al.
·
Annals of Oncology
PDF
27O Master gene regulation activity and methylation data reveals common patterns in well differentiated neuroendocrine tumors (NETs) from different tumor sites
2023
·
C. Carretero-Puche
, B. Antón Pascual
, et al.
·
ESMO Open
PDF
34P Genomic profiling of NEN patients: Prognostic and therapeutic relevance
2023
·
B. Antón Pascual
, A. Modrego
, et al.
·
ESMO Open
Author response for " MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms"
2023
·
Beatriz Soldevilla
, Alberto Lens‐Pardo
, et al.
·
Publons reviews and discussion
Author response for " MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms"
2022
·
Beatriz Soldevilla
, Alberto Lens‐Pardo
, et al.
·
Publons reviews and discussion
Abstract 355: Molecular characterization of BRAF V600E CRC in response to Src-targeted therapy
2022
·
Beatriz Rubio Cuesta
, Beatriz Gil Calderón
, et al.
·
Cancer Research
Abstract 2289: Comprehensive multiomic analysis reveals different subtypes in neuroendocrine tumors from multiple origins
2022
·
Carlos Carretero Puche
, Beatriz Soldevilla
, et al.
·
Cancer Research
Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq
2021
·
Fustero-Torre, Coral
, Jiménez-Santos, María José
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
1164P Prognostic value of miRNA profiling in neuroendocrine neoplasias (NENs) from lung and gastroenteropancreatic (GEP) origin
2020
·
P. Espinosa-Olarte
, B. Soldevilla
, et al.
·
Annals of Oncology
1158MO Metabolomic profile of advanced neuroendocrine cancer patients
2020
·
B. Soldevilla
, A. Lens-Pardo
, et al.
·
Annals of Oncology
Immune subtype in Colorectal Cancer: molecular, functional characterization and clinical implications
2019
·
Carlos Carretero Puche
·
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Show more works
View as search
Works count:
41
Citation count:
389
H-index:
8
I10-index:
6
Year
Topic
Type